Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medtronic (MDT) is encouraged by robust and consistent constant currency growth in the RTG business over the last few quarters.

Medtronic (MDT) to Post Q1 Earnings: Will RTG Aid the Stock?

Edwards Lifesciences

Shares of Medtronic and Edwards Lifesciences jumped Friday after the Food and Drug Administration approved their TAVR heart-valve replacement systems for healthier and younger patients.

Skip Open-Heart Surgery: TAVR OK'd In Healthier Patients; Stocks Pop

Medtronic's (MDT) successful execution of growth policies should aid earnings results in the fiscal first quarter.

Medtronic (MDT) to Report Q1 Earnings: What's in Store?

Extra Space Storage

Kimberly-Clark

Oracle

iShares Preferred and Income Securities ETF 

Volatility got you down? Dividend stocks are the answer.

5 Dependable Dividend Stocks To Buy

Becton, Dickinson and Co.

Boston Scientific

On its advisory list, the FDA suggests that doctors should point out the risks and benefits of all available PAD treatment options to their patients.

FDA Resets PAD Guidelines: The Road Ahead for Device Makers

Medtronic (MDT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Medtronic (MDT) Hits Fresh High: Is There Still Room to Run?

Abbott Labs

Baxter

Illumina

Intuitive Surgical

Johnson & Johnson

Stryker

Market caps for these medical device stocks are big. Most of them have been big winners, too.

10 Biggest Medical Device Stocks

Varian Medical Systems

In the wake of the U.S. tariff and Chinese retaliation, the MedTech industry players (with production houses in China) are facing huge bottom line pressure.

Will USTR's 25% Tariff Exemption Spell Relief for MedTech?

As India moves toward self-sufficiency, U.S. MedTech bigwigs fret over possible losses.

US-India Trade Tensions Rise: 3 Stocks in the Line of Fire

Cerner

The whole MedTech community finds a reason to cheer over with the FDA's recent proposal for Software as a Medical Device.

Tap AI-Powered Medical Device Stocks as FDA Bolsters SaMD

Amgen

Eli Lilly

Merck

Novartis

Pfizer

Thermo Fisher Scientific

UnitedHealth Group

How big does a company's market cap need to be to make the top 10 list of healthcare stocks? $111 billion.

The 10 Biggest Healthcare Stocks

Positive outcomes prove to be a major breakthrough for Medtronic (MDT) in the growing field of ventricular assist devices.

Medtronic Releases Positive Results of LATERAL Clinical Trial

Palo Alto Networks

The Trump administration will exempt 110 Chinese products, from medical equipment to key capacitors, from hefty tariffs, it said on Tuesday, offering relief to some U.S. firms which have said the taxes harm their bottom lines.

U.S. exempts some medical, electronic devices from China tariffs

Medtronic’s diabetes care business could grow in high-single-digits from $2.4 billion in fiscal 2019 to $2.8 billion in fiscal 2021, according to Trefis estimates. This growth will likely be led by expansion of MiniMed product line in international markets, and continued demand in the.

How Does Medtronic's Diabetes Care Business Compare To Its Peers?

Medtronic's (MDT) comprehensive biologics portfolio clubbed with Titan Spine's surface-enhanced titanium implants can enhance patient outcomes in spinal procedures.

Medtronic's Titan Spine Buyout to Boost Spine Surgery Range

Medtronic, the Food and Drug Administration and Homeland Security warned Thursday that potentially thousands of older model Medtronic insulin pumps are susceptible to hackers.
The post Medtronic Warns Thousands Of Insulin Pumps Could Be Open To Hackers appeared first on Investor's Business Daily.

Medtronic Warns Thousands Of Insulin Pumps Could Be Open To Hackers

MiniMed 508 Medtronic insulin pumps have cybersecurity problems that can't be updated or patched, and the company is recalling them as a result, the Food and Drug Administration said Thursday.

Medtronic recalls some insulin pumps as FDA warns they can be hacked

Medtronic PLC (NYSE: MDT)’s announcement that it is commencing an offer for more than $4 billion in debt securities should help the company manage its tax headwind, according to Morgan Stanley.

Morgan Stanley: Medtronic's $4B Financing Could Be 10-Cent EPS Tailwind

Medical devices manufacturer retires outstanding senior notes through 2 cash tender offers.

Medtronic to Extinguish Up to $4.17 Billion in Debt

AbbVie

Paychex

The stock charts of Medtronic, Paychex and AbbVie are poised to get the new trading week started with a bang.

3 Big Stock Charts for Monday: Medtronic, Paychex and AbbVie

Medtronic (MDT) reported earnings 30 days ago. What's next for the stock?

Medtronic (MDT) Up 8.5% Since Last Earnings Report: Can It Continue?

Medtronic's shares eased lower slightly on Friday morning.

Medtronic Delivers Dividends

Medtronic PLC (NYSE:MDT) files its latest 10-K with SEC for the fiscal year ended on April 30, 2019.

Medtronic PLC (MDT) Files 10-K for the Fiscal Year Ended on April 30, 2019

Aflac

Hormel Foods

Like dividends? You'll love these Dividend Aristocrats, each of which has the wherewithal to keep the dividends flowing for a long time to come.

Three Dividend Aristocrats to Buy and Hold Forever

Medtronic PLC MDT, +0.52% said Friday it will raise its quarterly dividend by 8%, to 54 cents a share from 50 cents a share.

News for Medtronic Stock (MDT)